Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/146836 |
Resumo: | The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS was transformed into free-flowing powder by solid adsorption technique followed by compression into tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant compared to plain sertraline (p |
id |
USP-31_ca38e3b857daaebf31edb3957ffa65de |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/146836 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertralineSNEDDSPhase diagramsSolubilityThermodynamic stabilityOral deliveryBioavailability The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS was transformed into free-flowing powder by solid adsorption technique followed by compression into tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant compared to plain sertraline (pUniversidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-06-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/14683610.1590/s2175-97902018000117232Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 1 (2018); e17232Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 1 (2018); e17232Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 1 (2018); e172322175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/146836/140365Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessRahman, Mohammad AkhlaquerMujahid, Mohammad2018-06-07T16:31:56Zoai:revistas.usp.br:article/146836Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2018-06-07T16:31:56Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
title |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
spellingShingle |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline Rahman, Mohammad Akhlaquer SNEDDS Phase diagrams Solubility Thermodynamic stability Oral delivery Bioavailability |
title_short |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
title_full |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
title_fullStr |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
title_full_unstemmed |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
title_sort |
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline |
author |
Rahman, Mohammad Akhlaquer |
author_facet |
Rahman, Mohammad Akhlaquer Mujahid, Mohammad |
author_role |
author |
author2 |
Mujahid, Mohammad |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Rahman, Mohammad Akhlaquer Mujahid, Mohammad |
dc.subject.por.fl_str_mv |
SNEDDS Phase diagrams Solubility Thermodynamic stability Oral delivery Bioavailability |
topic |
SNEDDS Phase diagrams Solubility Thermodynamic stability Oral delivery Bioavailability |
description |
The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS was transformed into free-flowing powder by solid adsorption technique followed by compression into tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant compared to plain sertraline (p |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-06-07 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/146836 10.1590/s2175-97902018000117232 |
url |
https://www.revistas.usp.br/bjps/article/view/146836 |
identifier_str_mv |
10.1590/s2175-97902018000117232 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/146836/140365 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 1 (2018); e17232 Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 1 (2018); e17232 Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 1 (2018); e17232 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222913382580224 |